A Phase 1 Dose Escalation Study of IPI-493

NCT00724425 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
53
Enrollment
INDUSTRY
Sponsor class

Stopped Drug exposure of retaspimycin HCl was superior to IPI-493, Infinity will focus exclusively on retaspimycin

Conditions

Interventions

Sponsor

Infinity Pharmaceuticals, Inc.